Sweden

Cantargia AB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Cantargia IND Application for CAN04 Approved by FDA

Lead Product(s): Nidanilimab,Pembrolizumab

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 04, 2020

Details:

CAN04, an antibody targeting IL1RAP, is currently being investigated for treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer (PDAC) in phase IIa clinical development.

Alligator Bioscience AB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Alligator Bioscience Increases Focus on Clinical Development

Lead Product(s): ATOR-1015

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 07, 2020

Details:

Study OC5-DB-02 (ePHex) is a 12-month randomized Phase 3 study to evaluate the efficacy and safety of Oxabact OC5 in adults and children with primary hyperoxaluria (PH) of all types.

Lidds

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Additional patients treated in LIDDS clinical study NZ-DTX-001

Lead Product(s): Docetaxel Trihydrate

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 01, 2020

Details:

Dose escalation in the Phase I study NZ-DTX is proceeding according to the protocol, with additional patients being treated at a higher dose level of NZ-DTX.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Product Type

Companies

Cantargia AB

Cantargia IND Application for CAN04 Approved by FDA

Alligator Bioscience AB

Alligator Bioscience Increases Focus on Clinical Development

Lidds

Additional patients treated in LIDDS clinical study NZ-DTX-001